Sandra P. Susanibar Adaniya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sandra P. Susanibar Adaniya has a total of 313 co-authors. Here are the top co-authors by number of shared publications:
- Alfred L. Garfall
Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
48 shared publications - Wei-Ting Hwang
Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
37 shared publications - Shambavi Richard
Department of Medicine, Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA
35 shared publications - Aimaz Afrough
UT Southwestern Medical Center, Dallas, TX
34 shared publications - Andrew Jay Portuguese
Fred Hutchinson Cancer Center, Seattle, WA
34 shared publications - Christopher James Ferreri
Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, USA
34 shared publications
Latest Publications
- 5 August 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
Evaluating Artificial Intelligence Translation Tools for Language Equivalence of Oncology-Informed Consent Forms From English to Spanish
PURPOSE: Approximately 8% of the US population speaks primary languages other than English. Limited English proficiency (LEP) contributes to under-representation of Hispanic patients in oncology clinical trials. Although certified translation services exist, they are time-consuming and costly. Artificial intelligence (AI)–generated translations of informed consent forms (ICFs) could provide low-cost alternatives, but data on accuracy and safety remain limited. We evaluated language equivalence of English-to-Spanish translations for three oncology clinical trial ICFs using two general-purpose AI translation tools (DeepL Pro and ChatGPT-4o) and a medically trained AI translation tool (Med_English2Spanish) compared with certified translations. METHODS: Translational equivalence was assessed using a five-point Likert scale on five domains: Semantic, Idiomatic, Experiential, Conceptual, and Safety. Two native Spanish-speaking bilingual board-certified physicians independently scored each translation. Weighted Cohen's kappa determined inter-rater reliability, and the two-sample t-test compared AI-generated and certified translations. RESULTS: Weighted Cohen's kappa (0.95, 95% CI 0.85 to 0.97) exhibited high inter-rater agreement. Certified translations exhibited the highest equivalence (mean = 4.99, SD = 0.02). ChatGPT-4o similarly demonstrated high equivalence (mean = 4.89, SD = 0.17). DeepL Pro scored well (mean = 4.43, SD = 0.07) but lower than certified translation ( P < 0.001). Med_English2Spanish demonstrated the lowest degree of equivalence (mean = 3.32, SD = 0.40) compared with certified translations ( P < 0.001). CONCLUSION: Low-cost AI translations of ICFs exhibited variable language equivalence compared with certified translations across several domains. ChatGPT-4o scored nearly equivalent across domains in translating procedural trial information. While AI-generated translations are currently not suitable for clinical deployment without human review, this exploratory study supports further analysis of AI translation tools for reducing language barriers to LEP population enrollment.
- 5 August 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
Evaluating Artificial Intelligence Translation Tools for Language Equivalence of Oncology-Informed Consent Forms From English to Spanish
PURPOSE: Approximately 8% of the US population speaks primary languages other than English. Limited English proficiency (LEP) contributes to under-representation of Hispanic patients in oncology clinical trials. Although certified translation services exist, they are time-consuming and costly. Artificial intelligence (AI)–generated translations of informed consent forms (ICFs) could provide low-cost alternatives, but data on accuracy and safety remain limited. We evaluated language equivalence of English-to-Spanish translations for three oncology clinical trial ICFs using two general-purpose AI translation tools (DeepL Pro and ChatGPT-4o) and a medically trained AI translation tool (Med_English2Spanish) compared with certified translations. METHODS: Translational equivalence was assessed using a five-point Likert scale on five domains: Semantic, Idiomatic, Experiential, Conceptual, and Safety. Two native Spanish-speaking bilingual board-certified physicians independently scored each translation. Weighted Cohen's kappa determined inter-rater reliability, and the two-sample t-test compared AI-generated and certified translations. RESULTS: Weighted Cohen's kappa (0.95, 95% CI 0.85 to 0.97) exhibited high inter-rater agreement. Certified translations exhibited the highest equivalence (mean = 4.99, SD = 0.02). ChatGPT-4o similarly demonstrated high equivalence (mean = 4.89, SD = 0.17). DeepL Pro scored well (mean = 4.43, SD = 0.07) but lower than certified translation ( P < 0.001). Med_English2Spanish demonstrated the lowest degree of equivalence (mean = 3.32, SD = 0.40) compared with certified translations ( P < 0.001). CONCLUSION: Low-cost AI translations of ICFs exhibited variable language equivalence compared with certified translations across several domains. ChatGPT-4o scored nearly equivalent across domains in translating procedural trial information. While AI-generated translations are currently not suitable for clinical deployment without human review, this exploratory study supports further analysis of AI translation tools for reducing language barriers to LEP population enrollment.
- Open Access
Mast Cells Enhance Myeloma Engraftment and Promote Bone Destruction in the NSG-hIL6 Patient Derived Xenograft Model
Multiple myeloma remains a fatal, incurable disease. Most therapies are targeted to the cancer cell or T cell engagement. Little is known about the supporting myeloma microenvironment and its contribution to tumor fitness. Here, we expand upon the observation of human mast cells in the NSG-hIL6 myeloma patient derived xenograft mouse model to show mast cells decrease time to engraftment, promote increased myeloma engraftment and cause myeloma bone disease. We identify 10 mast cell secreted factors that together improve the survival of patient myeloma cells in vitro. Our results highlight the versatility of the NSG-hIL6 model to study microenvironmental interactions between human bone marrow cells and myeloma and confirm prior suggestions that clinical signs of disease, such as osteolytic lesions, may at least partially be related to non-malignant bone marrow microenvironmental cells, such as mast cells.
Open AccessMast Cells Enhance Myeloma Engraftment and Promote Bone Destruction in the NSG-hIL6 Patient Derived Xenograft Model
Multiple myeloma remains a fatal, incurable disease. Most therapies are targeted to the cancer cell or T cell engagement. Little is known about the supporting myeloma microenvironment and its contribution to tumor fitness. Here, we expand upon the observation of human mast cells in the NSG-hIL6 myeloma patient derived xenograft mouse model to show mast cells decrease time to engraftment, promote increased myeloma engraftment and cause myeloma bone disease. We identify 10 mast cell secreted factors that together improve the survival of patient myeloma cells in vitro. Our results highlight the versatility of the NSG-hIL6 model to study microenvironmental interactions between human bone marrow cells and myeloma and confirm prior suggestions that clinical signs of disease, such as osteolytic lesions, may at least partially be related to non-malignant bone marrow microenvironmental cells, such as mast cells.
- Open Access
- 29 April 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (5) , e71900
When Timing Matters Most: Early Relapse Outweighs Baseline Risk in Myeloma
Multiple myeloma outcomes vary widely, with risk stratification typically based on baseline characteristics. Functionally high‐risk multiple myeloma (FHRMM), defined by early relapse within 12 months of initial therapy or autologous stem cell transplant, is associated with poor prognosis. However, the continued prognostic impact of baseline high‐risk features within the FHRMM cohort remains unclear. This study analyzed 181 FHRMM patients from the CoMMpass dataset, categorized into standard‐risk (SRG) and high‐risk (HRG) groups based on baseline cytogenetics and ISS stage. Despite SRG patients possessing more favorable baseline risk profiles, including lower SKY92 scores, their overall survival (OS) was not significantly different from HRG patients (20.7 vs. 18.1 months, p = 0.059). Treatment regimens and response rates were comparable between groups. Within the FHRMM cohort, only baseline ISS stage I retained prognostic significance for OS. In conclusion, FHR status overrides traditional baseline risk factors in determining prognosis. Patients experiencing early relapse should be considered uniformly high‐risk, highlighting the need for effective salvage therapies and consideration of novel treatments like CAR T‐cell therapies.
- 29 April 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (5) , e71900
Open AccessWhen Timing Matters Most: Early Relapse Outweighs Baseline Risk in Myeloma
Multiple myeloma outcomes vary widely, with risk stratification typically based on baseline characteristics. Functionally high‐risk multiple myeloma (FHRMM), defined by early relapse within 12 months of initial therapy or autologous stem cell transplant, is associated with poor prognosis. However, the continued prognostic impact of baseline high‐risk features within the FHRMM cohort remains unclear. This study analyzed 181 FHRMM patients from the CoMMpass dataset, categorized into standard‐risk (SRG) and high‐risk (HRG) groups based on baseline cytogenetics and ISS stage. Despite SRG patients possessing more favorable baseline risk profiles, including lower SKY92 scores, their overall survival (OS) was not significantly different from HRG patients (20.7 vs. 18.1 months, p = 0.059). Treatment regimens and response rates were comparable between groups. Within the FHRMM cohort, only baseline ISS stage I retained prognostic significance for OS. In conclusion, FHR status overrides traditional baseline risk factors in determining prognosis. Patients experiencing early relapse should be considered uniformly high‐risk, highlighting the need for effective salvage therapies and consideration of novel treatments like CAR T‐cell therapies.
- Open Access
- 28 April 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1) , 64
Immune effector cell-associated enterocolitis post-BCMA directed CAR T-cell therapy: insights from a multicenter case series
- 28 April 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1) , 64
Open AccessImmune effector cell-associated enterocolitis post-BCMA directed CAR T-cell therapy: insights from a multicenter case series
- Open Access
- 17 February 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (4) , 1395-1399
Outcomes of radiation integrated with T-cell–engaging bispecific antibodies in relapsed/refractory multiple myeloma
- 17 February 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (4) , 1395-1399
Open AccessOutcomes of radiation integrated with T-cell–engaging bispecific antibodies in relapsed/refractory multiple myeloma
- Top Cited Papers
- 15 January 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (2) , 702-716
CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy
B cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of multiple myeloma but can cause unique toxicities, including cranial nerve palsy, parkinsonism and enterocolitis, which we refer to collectively as CAR T cell therapy-associated immune-related adverse events (CirAEs). Among 198 patients treated with ciltacabtagene autoleucel or idecabtagene vicleucel (June 2021–December 2024), 27 (13.6%) developed CirAEs. This included one remarkable case with three distinct CirAEs in association with an extreme CD4+ CAR T cell expansion (peak lymphocytes: 197 × 103 per microliter), which was abrogated in vitro by CCR5 inhibition. CirAEs were associated with significantly higher non-relapse mortality (hazard ratio = 5.2, P = 0.006), and independent risk factors included ciltacabtagene autoleucel (odds ratio = 4.5, P = 0.058), peak absolute lymphocyte count ≥ 2.4 × 103 per microliter in the first 14 days post-infusion (odds ratio = 4.3, P < 0.001) and apheresis CD4:CD8 ratio > 1 (odds ratio = 2.6, P = 0.048). We identified marked CD4+ CAR T cell infiltration in all available CirAE tissues, including cerebrospinal fluid during neurologic CirAEs, implicating CD4+ CAR T cell therapy as a key mediator of these toxicities.
- 15 January 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (2) , 702-716
Top Cited PapersCD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy
B cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of multiple myeloma but can cause unique toxicities, including cranial nerve palsy, parkinsonism and enterocolitis, which we refer to collectively as CAR T cell therapy-associated immune-related adverse events (CirAEs). Among 198 patients treated with ciltacabtagene autoleucel or idecabtagene vicleucel (June 2021–December 2024), 27 (13.6%) developed CirAEs. This included one remarkable case with three distinct CirAEs in association with an extreme CD4+ CAR T cell expansion (peak lymphocytes: 197 × 103 per microliter), which was abrogated in vitro by CCR5 inhibition. CirAEs were associated with significantly higher non-relapse mortality (hazard ratio = 5.2, P = 0.006), and independent risk factors included ciltacabtagene autoleucel (odds ratio = 4.5, P = 0.058), peak absolute lymphocyte count ≥ 2.4 × 103 per microliter in the first 14 days post-infusion (odds ratio = 4.3, P < 0.001) and apheresis CD4:CD8 ratio > 1 (odds ratio = 2.6, P = 0.048). We identified marked CD4+ CAR T cell infiltration in all available CirAE tissues, including cerebrospinal fluid during neurologic CirAEs, implicating CD4+ CAR T cell therapy as a key mediator of these toxicities.
- 1 January 2026
- Published by American College of Physicians in Annals of Internal Medicine: Clinical Cases
- Vol. 5 (1)
When Sarcoidosis Looks Like Myeloma: A Diagnostic Pitfall
- 1 January 2026
- Published by American College of Physicians in Annals of Internal Medicine: Clinical Cases
- Vol. 5 (1)
When Sarcoidosis Looks Like Myeloma: A Diagnostic Pitfall
- Open Access
- 28 November 2025
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1)
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience
Teclistamab, a bispecific antibody targeting B-cell maturation antigen (BCMA), is effective in relapsed or refractory multiple myeloma (RRMM), but its impact on patients with soft tissue plasmacytomas is unclear. We studied 385 RRMM patients treated with teclistamab at 13 U.S. centers through September 2023, with follow-up to April 2024. Soft tissue plasmacytomas were classified as true extramedullary disease (EMD; not contiguous with bone) or paraskeletal plasmacytomas (PSK; contiguous with bone). Patients with the simultaneous presence of both were classified as true-EMD, reflecting its adverse prognosis. Of those, 109 (28%) had true EMD, 33 (9%) had PSK, and 243 (63%) had no soft tissue plasmacytoma (No-STP). Median follow-up was 9.9 months. Overall response rates were 38% in true-EMD, 54.1% in PSK, and 62.4% in No-STP ( p < 0.001). Median progression-free survival (PFS) was 1.4 months in true-EMD, 6.51 months in PSK, and 8.95 months in No-STP ( p < 0.0001). Median overall survival (OS) was 9.54 months for true EMD, 13.1 months for PSK, and not reached in No-STP ( p = 0.00012). In multivariable analysis, true-EMD was independently associated with inferior PFS and OS, while PSK showed numerically lower outcomes. These findings highlight the need for tailored strategies in patients with soft tissue plasmacytomas, particularly those with true-EMD.
- 28 November 2025
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1)
Open AccessThe impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience
Teclistamab, a bispecific antibody targeting B-cell maturation antigen (BCMA), is effective in relapsed or refractory multiple myeloma (RRMM), but its impact on patients with soft tissue plasmacytomas is unclear. We studied 385 RRMM patients treated with teclistamab at 13 U.S. centers through September 2023, with follow-up to April 2024. Soft tissue plasmacytomas were classified as true extramedullary disease (EMD; not contiguous with bone) or paraskeletal plasmacytomas (PSK; contiguous with bone). Patients with the simultaneous presence of both were classified as true-EMD, reflecting its adverse prognosis. Of those, 109 (28%) had true EMD, 33 (9%) had PSK, and 243 (63%) had no soft tissue plasmacytoma (No-STP). Median follow-up was 9.9 months. Overall response rates were 38% in true-EMD, 54.1% in PSK, and 62.4% in No-STP ( p < 0.001). Median progression-free survival (PFS) was 1.4 months in true-EMD, 6.51 months in PSK, and 8.95 months in No-STP ( p < 0.0001). Median overall survival (OS) was 9.54 months for true EMD, 13.1 months for PSK, and not reached in No-STP ( p = 0.00012). In multivariable analysis, true-EMD was independently associated with inferior PFS and OS, while PSK showed numerically lower outcomes. These findings highlight the need for tailored strategies in patients with soft tissue plasmacytomas, particularly those with true-EMD.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables and Figures from Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy
Supplemental tables: (1) Subject characteristics. (2) Cytogenetic profiles and high-risk features. (3) Prior treatment exposures and refractoriness. (4) CAR T cell product characteristics. (5) Products that did not meet target dose. (6) Adverse events of grade 3-4. (7) Cytokine release syndrome and ICANS. (8). Maintenance therapy. Supplemental Figures: (1) Study schematic and subject disposition, (2) Correlates of manufacturing success, (3) Hematopoietic recovery, (4) Post-infusion T cell phenotypes, (5) Correlates of in vivo expansion and manufacturing success, (6) Late post-infusion CAR T cell re-expansion, (7) Soluble BCMA, (8) Late-onset clinical responses, (9) MM cell BCMA expression, (10) Pre- and post-treatment Sox2-specific T cell responses in CART-BCMA monotherapy patients, (11) Pre- and post-treatment Sox2-specific T cell responses in CART-BCMA + huCART19 combination therapy patients, (12) Sustained post-treatment SOX2-specific T-cell responses.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables and Figures from Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy
Supplemental tables: (1) Subject characteristics. (2) Cytogenetic profiles and high-risk features. (3) Prior treatment exposures and refractoriness. (4) CAR T cell product characteristics. (5) Products that did not meet target dose. (6) Adverse events of grade 3-4. (7) Cytokine release syndrome and ICANS. (8). Maintenance therapy. Supplemental Figures: (1) Study schematic and subject disposition, (2) Correlates of manufacturing success, (3) Hematopoietic recovery, (4) Post-infusion T cell phenotypes, (5) Correlates of in vivo expansion and manufacturing success, (6) Late post-infusion CAR T cell re-expansion, (7) Soluble BCMA, (8) Late-onset clinical responses, (9) MM cell BCMA expression, (10) Pre- and post-treatment Sox2-specific T cell responses in CART-BCMA monotherapy patients, (11) Pre- and post-treatment Sox2-specific T cell responses in CART-BCMA + huCART19 combination therapy patients, (12) Sustained post-treatment SOX2-specific T-cell responses.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy
We conducted a phase I clinical trial of anti-BCMA chimeric antigen receptor T cells (CART-BCMA) with or without anti-CD19 CAR T cells (huCART19) in multiple myeloma (MM) patients responding to third- or later-line therapy (phase A, N = 10) or high-risk patients responding to first-line therapy (phase B, N = 20), followed by early lenalidomide or pomalidomide maintenance. We observed no high-grade cytokine release syndrome (CRS) and only one instance of low-grade neurologic toxicity. Among 15 subjects with measurable disease, 10 exhibited partial response (PR) or better; among 26 subjects responding to prior therapy, 9 improved their response category and 4 converted to minimal residual disease (MRD)–negative complete response/stringent complete response. Early maintenance therapy was safe, feasible, and coincided in some patients with CAR T-cell reexpansion and late-onset, durable clinical response. Outcomes with CART-BCMA + huCART19 were similar to CART-BCMA alone. Collectively, our results demonstrate favorable safety, pharmacokinetics, and antimyeloma activity of dual-target CAR T-cell therapy in early lines of MM treatment.Significance:CAR T cells in early lines of MM therapy could be safer and more effective than in the advanced setting, where prior studies have focused. We evaluated the safety, pharmacokinetics, and efficacy of CAR T cells in patients with low disease burden, responding to current therapy, combined with standard maintenance therapy.This article is highlighted in the In This Issue feature, p. 101
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy
We conducted a phase I clinical trial of anti-BCMA chimeric antigen receptor T cells (CART-BCMA) with or without anti-CD19 CAR T cells (huCART19) in multiple myeloma (MM) patients responding to third- or later-line therapy (phase A, N = 10) or high-risk patients responding to first-line therapy (phase B, N = 20), followed by early lenalidomide or pomalidomide maintenance. We observed no high-grade cytokine release syndrome (CRS) and only one instance of low-grade neurologic toxicity. Among 15 subjects with measurable disease, 10 exhibited partial response (PR) or better; among 26 subjects responding to prior therapy, 9 improved their response category and 4 converted to minimal residual disease (MRD)–negative complete response/stringent complete response. Early maintenance therapy was safe, feasible, and coincided in some patients with CAR T-cell reexpansion and late-onset, durable clinical response. Outcomes with CART-BCMA + huCART19 were similar to CART-BCMA alone. Collectively, our results demonstrate favorable safety, pharmacokinetics, and antimyeloma activity of dual-target CAR T-cell therapy in early lines of MM treatment.Significance:CAR T cells in early lines of MM therapy could be safer and more effective than in the advanced setting, where prior studies have focused. We evaluated the safety, pharmacokinetics, and efficacy of CAR T cells in patients with low disease burden, responding to current therapy, combined with standard maintenance therapy.This article is highlighted in the In This Issue feature, p. 101